NASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free AVDL Stock Alerts $18.09 +0.79 (+4.57%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$17.26▼$18.1950-Day Range$12.55▼$18.0952-Week Range$9.50▼$18.85Volume985,700 shsAverage Volume873,061 shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$22.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Avadel Pharmaceuticals alerts: Email Address Avadel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside24.8% Upside$22.57 Price TargetShort InterestBearish11.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.04Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to $0.83 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.33 out of 5 starsMedical Sector504th out of 909 stocksPharmaceutical Preparations Industry232nd out of 424 stocks 3.5 Analyst's Opinion Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvadel Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.47% of the outstanding shares of Avadel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently decreased by 0.76%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVDL. Previous Next 3.4 News and Social Media Coverage News SentimentAvadel Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avadel Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows12 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.46) to $0.83 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -8.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -8.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 18.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More AVDL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVDL Stock News HeadlinesApril 21, 2024 | americanbankingnews.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Receives Consensus Recommendation of "Buy" from AnalystsApril 21, 2024 | money.usnews.comAvadel Pharmaceuticals plcApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 17, 2024 | americanbankingnews.comAvadel Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AVDL)April 16, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (AVDL)April 16, 2024 | americanbankingnews.comHead to Head Comparison: Avadel Pharmaceuticals (NASDAQ:AVDL) versus Ventyx Biosciences (NASDAQ:VTYX)April 11, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near FutureApril 2, 2024 | seekingalpha.comAvadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly RevolutionApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 1, 2024 | globenewswire.comAvadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare ConferenceMarch 17, 2024 | finance.yahoo.comAVDL Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comAVDL Apr 2024 25.000 callMarch 16, 2024 | finance.yahoo.comAVDL Apr 2024 10.000 putMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avadel Pharmaceuticals Amid Strong Q4 Performance and Promising Growth ProspectsMarch 5, 2024 | seekingalpha.comAvadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation OverhangMarch 5, 2024 | realmoney.thestreet.comAvadel Pharmaceuticals price target raised by $2 at Oppenheimer, here's whyMarch 5, 2024 | msn.comAvadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 ResultsMarch 5, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2023 Earnings Call TranscriptMarch 4, 2024 | globenewswire.comAvadel Pharmaceuticals Issues Statement On Patent LitigationMarch 4, 2024 | finanznachrichten.deAvadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 4, 2024 | globenewswire.comAvadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 3, 2024 | finance.yahoo.comAVDL Mar 2024 5.000 putMarch 1, 2024 | seekingalpha.comAvadel Pharmaceuticals Q4 2023 Earnings PreviewMarch 1, 2024 | finance.yahoo.comWith 62% ownership, Avadel Pharmaceuticals plc (NASDAQ:AVDL) boasts of strong institutional backingFebruary 26, 2024 | finance.yahoo.comAvadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4February 25, 2024 | benzinga.comAvadel Pharmaceuticals Stock (NASDAQ:AVDL) Earnings Dates and Earning CallsFebruary 16, 2024 | finance.yahoo.comAVDL Jan 2025 20.000 callSee More Headlines Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today4/23/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVDL CUSIPN/A CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees154Year Founded2015Price Target and Rating Average Stock Price Target$22.57 High Stock Price Target$29.00 Low Stock Price Target$16.00 Potential Upside/Downside+24.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,280,000.00 Net MarginsN/A Pretax Margin-574.96% Return on Equity-198.06% Return on Assets-84.51% Debt Debt-to-Equity RatioN/A Current Ratio3.64 Quick Ratio3.36 Sales & Book Value Annual Sales$27.96 million Price / Sales58.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book18.46Miscellaneous Outstanding Shares90,580,000Free Float86,954,000Market Cap$1.64 billion OptionableOptionable Beta1.60 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Gregory J. Divis Jr. (Age 57)CEO & Director Comp: $753.69kMr. Thomas S. McHugh (Age 59)Senior VP, Principal Financial and Accounting Officer & CFO Comp: $526kMr. Richard J. Kim (Age 55)Chief Commercial Officer Comp: $548.44kMr. Jerad G. SeurerGeneral Counsel & Company SecretaryMr. Gregory J. Davis (Age 59)VP of Corporate and Business Development Mr. Mark W. ElrodVice President of SalesMs. Angie WoodsVice President of People & CultureDr. Jordan S. Dubow M.D. (Age 45)Consultant Comp: $727.93kDr. Jason M. VaughnSenior Vice President of Technical OperationsMs. Jennifer Gudeman PharmDSenior Vice President of Medical & Clinical AffairsMore ExecutivesKey CompetitorsHarmony BiosciencesNASDAQ:HRMYSupernus PharmaceuticalsNASDAQ:SUPNAmneal PharmaceuticalsNASDAQ:AMRXStructure TherapeuticsNASDAQ:GPCRTaro Pharmaceutical IndustriesNYSE:TAROView All CompetitorsInsiders & InstitutionsWealth Effects LLCSold 152,100 shares on 4/23/2024Ownership: 2.500%Vivo Capital LLCSold 124,329 shares on 4/22/2024Ownership: 4.385%Investors Asset Management of Georgia Inc. GA ADVSold 19,100 shares on 4/22/2024Ownership: 0.096%Claro Advisors LLCBought 10,165 shares on 4/18/2024Ownership: 0.011%Quarry LPBought 8,500 shares on 2/20/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions AVDL Stock Analysis - Frequently Asked Questions Should I buy or sell Avadel Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares. View AVDL analyst ratings or view top-rated stocks. What is Avadel Pharmaceuticals' stock price target for 2024? 7 equities research analysts have issued 1 year price targets for Avadel Pharmaceuticals' stock. Their AVDL share price targets range from $16.00 to $29.00. On average, they predict the company's share price to reach $22.57 in the next twelve months. This suggests a possible upside of 24.8% from the stock's current price. View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts. How have AVDL shares performed in 2024? Avadel Pharmaceuticals' stock was trading at $14.12 at the start of the year. Since then, AVDL shares have increased by 28.1% and is now trading at $18.09. View the best growth stocks for 2024 here. When is Avadel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AVDL earnings forecast. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its earnings results on Monday, March, 4th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.04. The company earned $19.45 million during the quarter, compared to analysts' expectations of $17.41 million. During the same period in the previous year, the business posted ($0.44) EPS. What ETFs hold Avadel Pharmaceuticals' stock? ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and AdvisorShares Dorsey Wright ADR ETF (AADR).Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY). Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vivo Capital LLC (4.39%), Wealth Effects LLC (2.50%), Investors Asset Management of Georgia Inc. GA ADV (0.10%) and Claro Advisors LLC (0.01%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVDL) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
